Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA.
Photoswitch Biosciences, Inc., Menlo Park, CA, USA.
Sci Rep. 2017 Apr 13;7:45487. doi: 10.1038/srep45487.
Photoswitch compounds such as DENAQ confer light-sensitivity on endogenous neuronal ion channels, enabling photocontrol of neuronal activity without genetic manipulation. DENAQ treatment restores both retinal light responses and visual behaviors in rodent models of Retinitis pigmentosa. However, retinal photosensitization requires a high dose of DENAQ and disappears within several days after treatment. Here we report that BENAQ, an improved photoswitch, is 20-fold more potent than DENAQ and persists in restoring visual responses to the retina for almost 1 month after a single intraocular injection. Studies on mice and rabbits show that BENAQ is non-toxic at concentrations 10-fold higher than required to impart light-sensitivity. These favorable properties make BENAQ a potential drug candidate for vision restoration in patients with degenerative blinding diseases.
光开关化合物,如 DENAQ,使内源性神经元离子通道具有光敏感性,从而能够在不进行基因操作的情况下对神经元活动进行光控。DENAQ 处理恢复了色素性视网膜炎啮齿动物模型中的视网膜光反应和视觉行为。然而,视网膜光致敏需要 DENAQ 的高剂量,并且在治疗后几天内消失。在这里,我们报告说,BENAQ,一种改良的光开关,比 DENAQ 强 20 倍,并且在单次眼内注射后几乎 1 个月内持续恢复对视网膜的视觉反应。在小鼠和兔子上的研究表明,BENAQ 在比赋予光敏感性所需的浓度高 10 倍的浓度下是无毒的。这些有利的特性使 BENAQ 成为恢复退行性致盲性疾病患者视力的潜在候选药物。